Adaptive Biotechnologies Corporation $ADPT Shares Bought by SG Americas Securities LLC

SG Americas Securities LLC increased its position in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) by 82.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 68,113 shares of the company’s stock after buying an additional 30,785 shares during the period. SG Americas Securities LLC’s holdings in Adaptive Biotechnologies were worth $1,019,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the company. JTC Employer Solutions Trustee Ltd grew its holdings in Adaptive Biotechnologies by 129.7% in the third quarter. JTC Employer Solutions Trustee Ltd now owns 11,735 shares of the company’s stock valued at $176,000 after purchasing an additional 6,626 shares during the period. Bouvel Investment Partners LLC grew its stake in shares of Adaptive Biotechnologies by 2.2% during the 3rd quarter. Bouvel Investment Partners LLC now owns 42,878 shares of the company’s stock valued at $641,000 after buying an additional 904 shares during the period. Yarbrough Capital LLC acquired a new stake in shares of Adaptive Biotechnologies during the 3rd quarter worth $427,000. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of Adaptive Biotechnologies in the 3rd quarter worth $809,000. Finally, Diversified Trust Co boosted its holdings in Adaptive Biotechnologies by 6.2% in the third quarter. Diversified Trust Co now owns 39,976 shares of the company’s stock valued at $598,000 after acquiring an additional 2,342 shares during the last quarter. Hedge funds and other institutional investors own 99.17% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on ADPT shares. Guggenheim started coverage on Adaptive Biotechnologies in a report on Tuesday, September 30th. They set a “buy” rating and a $20.00 target price for the company. BTIG Research increased their price objective on shares of Adaptive Biotechnologies from $19.00 to $21.00 and gave the stock a “buy” rating in a research report on Thursday, November 6th. Morgan Stanley started coverage on shares of Adaptive Biotechnologies in a research report on Monday, December 1st. They set an “equal weight” rating and a $21.00 price target for the company. Cowen reissued a “buy” rating on shares of Adaptive Biotechnologies in a research report on Wednesday, January 7th. Finally, Wall Street Zen upgraded Adaptive Biotechnologies from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $17.11.

Insiders Place Their Bets

In other Adaptive Biotechnologies news, CFO Kyle Piskel sold 4,290 shares of Adaptive Biotechnologies stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $18.00, for a total transaction of $77,220.00. Following the transaction, the chief financial officer owned 216,637 shares of the company’s stock, valued at $3,899,466. The trade was a 1.94% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Chad M. Robins sold 124,998 shares of the stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $15.59, for a total transaction of $1,948,718.82. Following the completion of the sale, the chief executive officer owned 2,584,243 shares of the company’s stock, valued at approximately $40,288,348.37. The trade was a 4.61% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 1,442,530 shares of company stock worth $24,610,748. Company insiders own 6.40% of the company’s stock.

Adaptive Biotechnologies Stock Performance

NASDAQ ADPT opened at $17.52 on Monday. The firm has a market capitalization of $2.67 billion, a PE ratio of -32.44 and a beta of 2.18. Adaptive Biotechnologies Corporation has a one year low of $6.26 and a one year high of $20.76. The company has a 50-day simple moving average of $16.60 and a 200-day simple moving average of $14.55.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.01. The firm had revenue of $93.97 million for the quarter, compared to the consensus estimate of $58.76 million. Adaptive Biotechnologies had a negative net margin of 31.50% and a negative return on equity of 58.40%. Adaptive Biotechnologies’s quarterly revenue was up 102.4% compared to the same quarter last year. During the same period last year, the firm posted ($0.22) EPS. Equities analysts forecast that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current year.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.